This includes a drastic reduction in the apolipoproteins ApoB-100 and ApoE and a concomitant increase in the enzyme protein-glutamine gamma-glutamyl-transferase TGM2 and the matrix metalloproteinase MMP9, which might be useful candidates as novel biomarkers of dystrophinopathy-related changes in the spleen (Dowling et al., 2019; Al-Khalili Szigyarto, 2020). Here, MMP9 is linked to neuromuscular disease caused by qualitative or quantitative defects of dystrophin.